Slashdot Mirror
Citing 'Moral Requirement To Make Money', Pharma CEO Jacks Drug Price 400% (arstechnica.com)
The chief executive of a small pharmaceutical company defended hiking the price of an essential antibiotic by more than 400 percent and told the Financial Times that he thinks "it is a moral requirement to make money when you can." From a report: Nirmal Mulye, CEO of the small Missouri-based drug company Nostrum Laboratories, raised the price of bottle of nitrofurantoin from $474.75 to $2,392 last month. The drug is a decades-old antibiotic used to treat urinary-tract infections caused by Escherichia coli and certain other Gram-negative bacteria. The World Health Organization lists nitrofurantoin as an essential medicine. In an interview with the FT, Mulye went on to say it was also a "moral requirement" to "sell the product for the highest price," and he explained that he was in "this business to make money."
Actually it was I, not Ms Mash, who posted this story.
I’m always amoused when these low-budget shkrelis claim to be defenders of the free market when they make insane price moves. If we actually did have a free market in pharma, we would be able to fill our prescriptions for this compound at the world market price of $18, as per the closing line that was oddly edited out of my post.
The only way price increases like this can be made to stick is to have the FDA on your side, preventing us from being able to compete. Time to rip out the FDA’s ability to keep competition out of the market. Let it manage testing, not price manipulation.
On a world scale, the US democratic party is on the right of the center of the political spectrum. Despite being in power for years, they still didn't implement basic social net such as free health care that are considered standard everywhere else in the developed world. Even right-wing political parties support the idea in most places.
There's fairly strong evidence against your primary assumption. Most drug discovery is done by academic, publicly funded researchers, who get paid fairly poorly considering their education, and the hazards of the field.
The ones who rake in the big profits are business and investor types who mostly buy and sell existing IP.
I'm Canadian, and I can assure you that our "socialised" system is:
So please, don't say our system is better than in the US. People are not dying in the streets up here, but when you have a condition, you better be patient. A patient patient.
I'm a Canadian too, and the circumstances you've cited are worst-case and relatively uncommon. Non-critical illnesses are at a lower priority than critical ones, but people get the care they need, regardless of the depth of their pockets. So yes, our system is better, in most ways.
"Oh no... he found the
Because these systems are always partially or entirely tax-funded this obviously means that wait times for some non-critical operations can be higher, because people in immediate risk take priority but this is true in the states as well. If you actually compare waiting times for a specialist for example, you'll note that US is pretty much on par with the UK, and that Canada is on the slower side of other universal model countries (which, is all advanced countries other than the US). I work for the largest health care district of the Finnish single payer health care system with about a million people under it, I can quote you some numbers (these are from 2015 because they're publicly available (Finnish only though), can't access the current stats from home). Of the 27 most common types of surgery, we had altogether 26 658 people in queue in 2015, of which 19,5 % waited for more than 6 months. The median wait time was 87 days. For the 2 heart-related surgery-types on the list (bypass and percutaneous coronary intervention the median was below 30 days). The question here is: would it be better for the uninsured in the US to wait a bit to get good health care from the existing system with public money, or wait til' they die or go bankrupt? Is it beneficial for the US economy as a whole to remain the only country where people have to go into debt due to medical problems?
Thing to realize is that this is about availability, not quality. Quality-wise the US model is not significantly better nor is it worse. In fact, quality-wise the system is just fine for the people who're insured, the main difference is that the lack of universal public insurance leaves some people outside of the system driving up deaths. And the far more commercialised nature of the systems drives up margins and administrative costs (which is a large part of the huge spending difference (about twice the average spending of comparable countries) between the US and the rest of the world. In fact, medicare for example is already cheaper (per head covered) costs-wise than private options, largely cause it has better costs-management and lower administrative costs).
The are plenty of universal models out there which aren't single payer like Canada or here. All the US would have to do to implement such would essentially be to allow medicare/medicaid like option for all , and it would likely bring total costs down in the long term and better care for everyone.
But sure, keep posting anecdotal stuff about wait times instead of the larger picture., that's always constructive!
"It is the business of the future to be dangerous" -Alfred North Whitehead
Not really. You don't found a pharma startup unless you've got a promising candidate already. Basic discovery happens mostly in universities. The academic researchers find something interesting, use animal models to work out the mechanism and test efficacy, and occasionally even do some human studies. Startups are then either spun out of the university, started independently in conjunction with one of the university researchers, or in some cases just troll through the published literature looking for good ideas. The startup, or sometimes a bigger pharma company, then runs the basic human trials, and, if successful, sells the drug (or the company) to one of the major pharma corps for marketing and distribution.
Basic discovery is still very much a publicly financed endeavour.